BaroPharm, an integrated pharmacy platform founded in 2019, has submitted a securities filing to the Financial Services Commission and entered the formal public offering stage for a KOSDAQ listing. The company plans to issue a total of 1.78 million shares at a hoped‑for price range of 16,400 KRW to 22,200 KRW per share, which would raise between 29.2 billion and 36.0 billion KRW. Mirae Asset Securities will act as the lead underwriter. Institutional investor demand forecasting is scheduled for October 22‑28, while the general subscription period is set for November 2‑3. BaroPharm aims to complete its KOSDAQ listing within the current year. The platform aggregates inventory and pricing information from multiple drug wholesalers, allowing users to compare options in a single location.
Analyse21 sept. 2026•1 min de lecture
BaroPharm Submits Securities Filing, Begins KOSDAQ IPO Process
BaroPharm filed a securities report with the Financial Services Commission and announced a public offering of 1.78 million shares, targeting a 16,400‑22,200 KRW price range, aiming for a KOSDAQ listing this year.
Compilé par l'équipe PharmaCountry · Source : KPA News
Évaluations
(0)
(0)
(0)
(0)
(0)
Plus d'articles
Voir tous les articlesRecherches & Rapports
Global Finished Dosage Manufacturing Landscape 2026
5 oct. 2026
Actualités réglementairesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept. 2026
Laissez votre note